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ABSTRACT 
In order to achieve the therapeutic purpose, the choice of the most suitable 
delivery route is of indisputable importance. Therefore, certain factors must 
be taken into consideration when delivering a active substance, namely its 
own properties, the disease to be diagnosed and the desired beneficial time. 
The active substances can be directly to the target tissue or organ or can be 
delivered by systemic routes. 
Introduction
The transfer of active substances in human body may be 
consummate by several anatomic routes. In order to achieve 
the therapeutic purpose, the choice of the most suitable 
delivery route is of indisputable importance. Therefore, certain 
factors must be taken into consideration when delivering a 
active substance, namely its own properties, the disease to be 
diagnosed and the desired beneficial time. The active 
substances can be directly to the target tissue or organ or can 
be delivered by systemic routes. Systemic active substance 
transferring routes are presented systematically in Table 1. 
Pharmaceutical treatments started plenty of decades, or even 
centuries ago either with the oral administration of solid pills 
or with injectables active chemical active substances. When 
either of these methods is applied, active substance dose 
maintenance in the body is accomplished by repeated 
deliveries. Despite the effectiveness of these treatments, dose 
peaks at administration times alternated with sub-beneficial 
active substance levels are inevitable. Therefore, the 
impossibility of controlling the active substance level over a 
long period of time constituted an important drawback. During 
the past two decades, new advancements and strategies have 
been developed to monitor certain parameters considered 
essential for improving the treatment performance such as the 
rate, period of time and targeting of transfer. This was the 
beginning of the so called active substance transfer systems. 
[1] 
The main purpose of using a DDS is, as implied, not only to 
transfer a biologically active compound in a controlled manner 
(time period and releasing rate) but also to persist the active 
substance   level in the body within beneficial window. 
Besides, one can direct the active compound towards a 
specific organ or tissue. The first two features were addressed 
by using active substance carriers, usually polymers (either 
biopolymers or synthetic polymers) which properties could be 
manipulated in order to enhance DDS efficiency. Although 
both natural and synthetic polymers are being used in the 
preparation of DDS, there are some profits that can be pointed 
to synthetic macromolecules. When the polymers are man-
made, it becomes possible to monitor some manner of 
polymer structure that allows generating tailor-made materials 
suitable to the desired biological advancement. Also, three-
dimensional structure as well as chemical composition can be 
monitored   in order to adjust materials properties and 
orientation of specifics functional groups that can collaborate 
with the active compound in spite of, consideration must be 
paid to molecular weight of fiber polymers which are not 
biodegradable. Since biodegradation does not always takes 
place, synthetic polymers must be diminished through renal 
elimination. [2] Therefore, they should present a uniform 
molecular weight distribution that fits under the entrance of 
renal elimination. As further defined in this paper, 
sustained/living radical polymerization is a very predictable 
and applied technology in order to produce well defined 
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macromolecular structures with definite range molecular 
weights dissemination. DDS present certain profits. These 
include important factors from minimize of active substance 
side-effects to enhanced patient compliance. In spite of, DDS 
disadvantages are also well-known, e.g., DDS final cost amid 
others. Targeted active compound transfer around the interest 
of the scientific community and therefore has authenticated 
excellent advancements over the last decade. The active 
compounds targeting accomplice the agreement of different 
areas associated to active compounds design, active 
compounds carriers, biological systems, genetic advancements   
and definitive design of new molecules. In order to maximise 
the capability of the current methods for active substance 
deliver, certain steps need to be consummate. The main goal is 
currently associated to transfer applicable active compounds at 
a desiderate target without any sign of degradation during the 
whole process. The advancement of a sustained delivery   
system that can dose orally, being less cost and less painful for 
the patients and at the same time exceedingly sufficient 
considering a specific disease represents a final target for the 
research community. DDS must possess some features. The 
system should be accepted by the specific target tissues. In 
fact, the transferring of the active substance in a specific area 
of the body is excessively important, in terms of lowering 
possible side effects of the active compounds, when enter non-
targeted organs and tissues. [3] 
 
Modified drug delivery system: The term modified-
discharge of active substance product is used to describe 
products that change the timing and the rate of discharge of 
the active substance compound. The modified drug delivery is 
defined as the drug to discharge the active substance for a 
longer period of a time. The modified drug delivery 
diminishes the side effects and adverse effects. The 
therapeutic efficacy of drug is enhanced. The modified drug 
release system involves the sustained and controlled and 
prolonged release systems. They may release the drug in a 
controlled or sustained manner for a prolong period.  [4]   
 
Extended-release drug products: The extended release 
dosage forms defined as the drug to release the extended 
period of the time. They may reduce the side effects and 
adverse effects. The dosing frequency is less when compared 
to the immediate release delivery.  
Examples of extended-release dosage forms include 
controlled-release, sustained-release, and long-acting drug 
products. [5] 
 
Delayed-discharge active substance products: The delayed 
drug delivery is defined as the the delayed system will 
discharge the active compound in a dosage form that releases 
a distinct portion of active substance after delivery of the 
active substance.  Enteric-coated dosage forms are the most 
common delayed-release products.  
 
Targeted-release drug products: The targeted drug delivery 
products are defined as the they will discharge the active 
substance at or a dosage form that releases drug at or near the 
designed physiologic site of action. Targeted-discharge dosage 
forms may have either immediate or extended-discharge 
characteristics. The word monitor release product was the term 
controlled-release drug product was contracted used to 
illustrate different types of oral extended-discharge  dosage 
forms, including along with  sustained-discharge , sustained-
action, prolonged-action, long-action, slow-release, and 
programmed active substance discharge. [6] 
 
Conventional Drug Delivery System: The conventional drug 
delivery is to deliver the drugs to the systemic circulation. The 
conventional drug delivery having the so many drawbacks the 
dosing frequency is less, they having the so many 
disadvantages like occurring of the side effects and adverse 
effects. The conventional dosage forms they will immediately 
discharge the dosing frequency is more. By passing of these 
problems the sustained release dosage farms are designed. The 
dosages forms will deliver   the drug up to the longer period 
reduce the side effects and adverse effects. To enhance the 
therapeutic efficacy of a drug. The sustained drug delivery is 
does not depending up on the time they release the drug up to 
sustained manner. The dosing frequency is less. The patent 
compliance will improve. Pharmaceutical products designed 
for oral transfer are mainly conventional active substance 
delivery systems, which are designed for immediate release of 
drug for rapid/immediate absorption, administration of the 
conventional dosage form by extra vascular route does not 
continue the drug level in blood for an extended period of 
time.[7] The conventional dosage forms like solution, 
suspension, capsule, tablets and suppository etc. have some 
limitations such as  
1) For sustained release preparation the drugs should have 
the shorter half life. The shorter half life of the products 
will eliminate quickly.  
2) A typical peak valley plasma concentration time profile is 
assemble which made steady state condition is different.       
3) The changes in the active substances they may lead to 
precipitation they undergo for the side effects and adverse 
effects.  [8] 
 
Oral Controlled Drug Delivery Systems: Oral controlled 
release drug delivery system is defined as the deliveries of 
drugs in a pre determine rate and pre determine time without 
any side and adverse effects. The oral drug delivery   is a 
system that provides continuous oral delivery of drugs at 
predictable and reproducible kinetics for a predetermined 
period throughout the course of GI transit and also the system 
that target the transfer of a active substance to a specific 
region within the GI tract for either a local or systemic action.  
 
Classification of Oral Controlled Release System  
A) Diffusion Controlled Systems  
I. Reservoir Devices  
II. Matrix Devices  
B) Dissolution controlled system 
 I. Matrix Dissolution Controlled System  
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II. Encapsulation Dissolution Controlled system  
C) Diffusion and Dissolution Controlled System.[9] 
 A) Diffusion Controlled Systems  
I. Reservoir Devices A core of active substance (the reservoir) 
enclosed by a polymeric membrane characterizes them. The 
nature of the membrane determines the rate of active 
substance discharge. The characteristics of reservoir diffusion 
systems are  
1. Zero order active substance discharge is possible.  
2. The active substance discharge rate is dependent on the type 
of polymer.  
3. High molecular weight compounds are difficult to transfer 
through the device. Coating and microencapsulation technique 
can be applied to formulate sub devices. [10] 
II. Matrix Devices: The matrix devices defined as the it is 
having the active substance dissolved   homogeneously in a 
matrix. The characteristics of the matrix diffusion system are 
 1. Zero order discharge cannot be produced.  
2. Easy to manufacture than reservoir devices.  
3. High molecule weight of substances are transferred through 
the devices.[11] 
B) Dissolution controlled systems:  
I. Matrix Dissolution Controlled System Aqueous dispersions, 
congealing, spherical agglomeration etc. can be used.  
II. Encapsulation Dissolution Control Particles, seeds or 
granules can be coated by technique such as 
microencapsulation.  
C) Diffusion and Dissolution Controlled System:  
The diffusion and dissolution controlled system is defined as 
the   bio erodible matrix the active substance is 
homogeneously dissolved in a matrix and they discharged 
either by bilging monitor mechanism or by hydrolysis and 
enzymatic attack.  [12]  
 
Types of Extended-Release Products: The extended drug 
release is defined as the  drug should be released in a 
predetermine rate and predetermine time with extended period 
of a time. The extended release substances shows the many 
advantages they are the reducing the side effects and adverse 
effects and release the drug in a longer period of time. The 
drug will reach the bio-availability in a pre determine time. 
The extended release substances include general 
advancements for release the drug into a site of action. 
General advancements to preparation an extended-discharge 
active substance product include the use of a matrix structure 
in which the active substance is suspended or dissolved, the 
use of a rate controlling membrane through which the drug 
diffuses, or a combination of both. For preparation of the 
extended release products the wide variety of the polymers are 
used such as the natural and synthetic polymers are used The 
natural polymers are such as the xanthin, tragacanth, guargum. 
The synthetic polymers such as the ethyl cellulose, HPMC, 
sodium alginate were used for development of the extended 
release products. The extended release products are discharged 
by the mechanism such as the dissolution, diffusion and 
permeation studies. [13]     
Factors effecting the Design and Performance of extended 
Release Products: The type of delivery system and route of 
administration of the drug presented in sustained drug delivery 
system may depend upon two properties. They are  
I. Physicochemical Properties of drugs  
II. Biological Factors. [14] 
 
Physicochemical Properties of Drugs  
 
Dose size: For designing of the dosage form the dose size is 
maximum required. For orally administered systems, there is 
an upper limit to the bulk size of the dose to be administered. 
In general a single dose of 0.5 to 1gm is considered 
maximum.[15] 
 
Ionization, PKa & Aqueous Solubility: The designing of the 
extended release dosage form the ionization and Pka and 
aqueous solubility is important. The pH Partition hypothesis 
simply states that the uninterrupted form of a active substance 
species will be alternative immersed through many body 
tissues. Therefore it is important to note the relationship 
between the PKa of the compound and its assimilative 
environment. For many substances, the site of maximum 
penetration will also be the area in which the active substance 
is least soluble. For traditional dosage forms the active 
substance can generally totally dissolve   in the stomach and 
then be penetrated in the alkaline pH of the intestine.[16] For 
sustained discharge  formulations much of the active 
substance will come in to the   small intestine in solid form. 
This means that the solubility of the active substance is likely 
to change several orders of magnitude during its discharge. 
Compounds with very low solubility are genetically 
controlled, since their discharge over the time course of a 
dosage form in the GIT will be limited by dissolution of the 
active substance. The lower limit for the solubility of a active 
substance to be formulated in a extended discharge system has 
been reported to be 0.1mg/ml. Thus for slightly soluble active 
substances, diffusional systems will be poor choice, since the 
concentration in solution will be low. For example 
Tetracycline has maximum solubility in the stomach and least 
solubility in the intestine where it is maximally absorbed. 
Other examples of drugs whose incorporation into sustained 
release systems are limited because of their poor aqueous 
solubility and slow dissolution rate are digoxin, warfarrin, 
griseofulvin and salicylamide. Very soluble drugs are also 
good candidates for the sustained release dosage forms.[17] 
  
Molecular size and diffusivity: The active substance is 
directly ability of drug to disperse through membrane is called 
diffusivity & diffusion coefficient is function of molecular 
size (or molecular weight). Commonly, values of diffusion 
coefficient for intermediate molecular weight active 
substances, through elastic polymer range from 10-8 to 10-9 
cm2 / sec. with values on the order of 10-8 being most 
common for active substances with molecular weight greater 
than 500, the diffusion coefficient in many polymers regularly 
are so small that they are difficult to quantify i.e. less than 16-
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12 cm2 /sec. Thus high molecular weight active substances 
and / or polymeric active substances should be expected to 
display very slow discharge kinetics in sustained discharge 
device applying diffusion through polymer membrane. 
[18][19] 
 
Partition coefficient: The designing of the extended release 
dosage forms the partition co efficient is very important 
parameter. The partition co efficient is more for the 
approximately   predominantly lipid soluble and easily 
absorbed through the   membranes resulting more 
bioavailability. The low partition co-efficient is not suitable 
for the designing of the dosage farms. These leads to the poor 
bio availability.  [20]     
 
Drug Stability: The active substances some are unsuitable in 
stomach, can be placed in a slowly soluble form and their 
discharge delayed until they reach the small intestine. Inspite 
of such a strategy would be destructive for active substances  
that either are precarious  in the small intestine (or) undergo 
considerable gut wall metabolism, as pointed out in the 
minimise  bioavailability of some anti cholinergic active 
compounds from controlled discharge production. In general 
the active substances, which are not stable in GIT 
environment, are poor candidates for oral sustained discharge 
forms.[21] 
  
Protein Binding: The protein binding is also necessary for the 
designing of the sustained drug delivery. In this many active 
substances are bind to the plasma proteins with it is well 
known that many drugs bind to plasma proteins with a 
complementary effecting on the duration of active substance 
action. Considering blood proteins are mainly re circulated 
and not eliminated active substance protein binding can serve 
as depot for active substance formulating   a longer discharge 
profile, especially if a high degree of drug binding occurs. [22] 
 
Biological Factors  
 
Biological Half-Life: The biological factors are mainly 
effecting on the sustained release preparation. The half life of 
the drug is low they suitable for the sustained release 
preparation the compounds should have the 2-3 hrs. The does 
not show any side effects and adverse effects. If drug should 
have the longer half life they do not suitable for the sustained 
release preparation. The compounds are having less half life 
they are suitable for the sustained release dosage forms these 
are excellent candidates for the sustained release dosage 
forms.      So the active substances, which have long -half life 
and short half- life, are poor candidates for sustained release 
dosage forms. Some examples of drug with half-lives of less 
than 2 hours are ampicillin, cephalexin, cloxacillin, 
furosemide, levodopa, penicillin G and propylthiouracil. [23] 
2. Absorption: The absorption is main important candidates 
for the designing of the dosage farms. The absorption of the 
active substance is most effectively suitable for the sustained 
release compound. The mostly selected active substances are 
the penetrated through the specialised transport system. The 
drug absorption through the gastrointestinal tract are poor 
candidates for the designing of the sustained release 
compounds. [24]   
 
Metabolism: The drugs which are incorporating into the 
sustained form the metabolism is important parameter. The 
mostly drugs under metabolism in liver with respective 
enzyme. The drugs which are metabolised before absorption 
either in the lumen or the tissue of the intestine can show 
minimising bioavailability from slower-transformation dosage 
form. Hence criteria for the drug to be applied for 
development sustained-Release dosage form is, [25] 
Drug should have low half-life.  
Drug should be freely soluble in water.   
Drug should have greater therapeutic window.  
 Drug should be penetrating throughout the GIT. 
 
Distribution: After the metabolism the undergo for 
distribution .The drugs which are distributed through the entire 
GIT. The drugs which are having high apparent distribution 
volume they effect elimination. The drugs are poor candidate 
for oral SR drug delivery system e.g. Chloroquine.[26] 
 
Monolithic Matrix System In pharmaceutical CRDDS 
 The monolithic matrix system is defined as the discharge the 
drug in a monitor manner technology. The preparation of the 
tablets by the direct compression method and dry granulation 
and wet granulation process. For preparation of the tablets 
many types of the polymers are using they are the natural type 
and synthetic polymers are used. The natural polymers are 
xanthin pectin, cellulose derivatives. The synthetic polymers 
are HPMC, Sodium alginate, ethyl cellulose.  [27] 
1. Chemical nature of the support.  
2. The physical state of the active substance.  
3. The matrix and changes in volume as the function of the 
time. 
 4. The routes of transformation.  
5. The discharge kinetics model .The classification of the 
matrix-based systems is based on the following criteria.   
Matrix structure 
 Release kinetics Controlled release properties  
Chemical nature and the properties of the applied release 
retardant(s). [28] 
 
Mechanism of Drug Release from Matrix Tablets: In 
erodible matrices, polymer erosion from the surface of the 
matrix determines the drug release; whilst in hydrophilic 
matrices, formation of the gel layer and its dynamics as a 
function of time determines the drug release. Gel layer 
thickness, which regulate the diffusion path length of the drug, 
resemble to the distance between the diffusion and erosion 
fronts. As the swelling process proceeds, the gel layer 
gradually becomes thicker, resulting in progressively slower 
active substance -release rates. [29]  
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